In daily clinical practice, mCRCs that are RAS-MT at the start of treatment and convert to aRAS-ML during the course of treatment may challenge anti-EGFR agents that were previously considered to be of no benefit in RAS-MT colorectal cancer, potentially significantly influencing treatment strategies. The gene discussed is EGFR; the disease is colorectal cancer.